McIntyre et al. reported that the shRNA knockdown of CAIX in colon cancer HCT116 and U87 glioblastoma xenografts enhanced the effect of antiangiogenic therapy with bevacizumab, resulting in a reduced tumour growth rate in vivo [80]. This evidence concerns the gene CA9 and neoplasm.